Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.30 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528479 | 0.81 | — | — | |
| SCHEMBL2301663 | 0.77 | PGK1 (0.33) | PGK1KCNN3 | |
| SCHEMBL11955179 | 0.77 | PGK1 (0.33) | PGK1KCNN3 | |
| SCHEMBL7807011 | 0.76 | ATF1 (0.34) | IGF1RPGK1KCNN3 | |
| SCHEMBL9586268 | 0.74 | IGF1R (0.32) | IGF1RPGK1KCNN3 | |
| SCHEMBL13172417 | 0.74 | TRPV1 (0.34) | PGK1KCNN3 | |
| SCHEMBL18398967 | 0.74 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL7808650 | 0.73 | KMT2A (0.50) | — | |
| SCHEMBL13194452 | 0.73 | KCNN3 (0.39) | PGK1KCNN3 | |
| SCHEMBL16635330 | 0.73 | LOXL2 (0.38) | PGK1KCNN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| EP-3810593-A1 | OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2021-04-28 | — | — | EP | disclosed |
| EP-3810136-A1 | OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2021-04-28 | — | — | EP | disclosed |
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-22 | — | — | US | disclosed |
| CN-112334461-A | OGA inhibitor compounds | 詹森药业有限公司 | 2021-02-05 | — | — | CN | disclosed |
| CN-112312908-A | OGA inhibitor compounds | 詹森药业有限公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2019243528-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243526-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| EP-2350008-B1 | METHOD FOR THE PREPARATION OF FUNCTIONALIZED TRIHALOMETHOXY SUBSTITUTED PYRIDINES | BAYER CROPSCIENCE AG (DE) | 2012-09-05 | — | — | EP | disclosed |
| EP-2350008-A1 | METHOD FOR THE PREPARATION OF FUNCTIONALIZED TRIHALOMETHOXY SUBSTITUTED PYRIDINES | Bayer CropScience AG (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010040461-A1 | METHOD FOR THE PREPARATION OF FUNCTIONALIZED TRIHALOMETHOXY SUBSTITUTED PYRIDINES | BAYER CROPSCIENCE AG (DE) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | IGF1R 2318/4885PGK1 193/4885KCNN3 4050/4885 |
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | IGF1R 2318/4885PGK1 193/4885KCNN3 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.